FORM PTO-1390 (Modified) U.S., PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 12-2004)

## TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

271529US0PCT U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/533081

INTERNATIONAL APPLICATION NO. PCT/JP03/13848

INTERNATIONAL FILING DATE 29 October 2003

PRIORITY DATE CLAIMED 29 October 2002

TITLE OF INVENTION QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF FLT3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME		
APPLICANT(S) FOR DO/EO/US Hisamaru HIRAI et al.		
Annlic	ant he	erewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:
1.	×	This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.
2. 3.	⊠	This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.  This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4.	$\boxtimes$	The US has been elected (Article 31).
5.	$\boxtimes$	A copy of the International Application as filed (35 U.S.C. 371 (c)(2))
		a.  is attached hereto (required only if not communicated by the International Bureau).
		b. 🗵 has been communicated by the International Bureau.
		c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
		a.  is attached hereto.
		b.  has been previously submitted under 35 U.S.C. 154(d)(4).
7.	$\boxtimes$	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
		a.   are attached hereto (required only if not communicated by the International Bureau).
		b.  have been communicated by the International Bureau.
		c.  have not been made; however, the time limit for making such amendments has NOT expired.
		d. 🛛 have not been made and will not be made.
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9.		An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11.	$\boxtimes$	A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12.	$\boxtimes$	A copy of the International Search Report (PCT/ISA/210).
lt	ems 1	13 to 23 below concern document(s) or information included:
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15.		A FIRST preliminary amendment.
16.		A SECOND or SUBSEQUENT preliminary amendment.
17.		A substitute specification.
18.		A power of attorney and/or change of address letter.
19.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
20.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).
21.		A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).
22.		Express Mail Label No.
23.	$\boxtimes$	Other items or information:
		Application Data Sheet Notice of Priority PCT/IB/304 PCT/IB/308 Request for Consideration of Documents Cited in International Search Report

JC12 Rec'd PCT/PTC 28 APR 2005

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. U.S. APPLICATION NO (if known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO. ATTORNEY'S DOCKET NUMBER PCT/JP03/13848 271529US0PCT 24. The following fees are submitted: Applicant use Office use \$300.00 \$300.00 \$200.00 \$200.00 \$400.00 \$900.00 TOTAL OF ABOVE CALCULATIONS = \$900.00 Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof. **Total Sheets** Extra Sheets Number of each additional 50 or RATE fraction thereof (round up to a whole - 100 = \$250.00 \$0.00 Surcharge of \$130.00 for furnishing the oath or declaration later than months from the \$130.00 earliest claimed priority\_date (37 CFR 1.492(e)). **NUMBER FILED** NUMBER EXTRA RATE Total claims - 20 = x \$50.00 \$0.00 Independent claims - 3 = \$200.00 \$0.00 MULTIPLE DEPENDENT CLAIMS (if applicable) \$360.00 \$0.00 TOTAL OF ABOVE CALCULATIONS = \$1,030.00 Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are \$0.00 reduced by 1/2. SUBTOTAL = \$1,030.00 Processing fee of \$130.00 for furnishing the English translation later than 30 months from \$130.00 the earliest claimed priority date (37 CFR 1.492(f)). **TOTAL NATIONAL FEE =** \$1,160.00 Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be \$0.00 accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property **TOTAL FEES ENCLOSED =** \$1,160.00 Amount to be refunded: Amount to be charged: \$ a. A check in the amount of \$ to cover the above fees is enclosed. Please charge my Deposit Account No. in the amount of to cover the above fees. A duplicate copy of this sheet is c. 🛮 The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 15-0030 . A duplicate copy of this sheet is enclosed. d. 🗵 Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card Information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO: Customer Number SIGNATURE Surinder Sachar 22850 Norman F. Oblon Registration No. 34,423 NAME 24,618 REGISTRATION NUMBER

DOCKET NO.: 271529US0PCT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Hisamaru HIRAI, et al. SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HEREWITH

INTERNATIONAL APPLICATION NO.: PCT/JP03/13848

INTERNATIONAL FILING DATE: October 29, 2003

FOR: QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF FLT3 AND MEDICINAL COMPOSITIONS CONTAINING

THE SAME

## REQUEST FOR CONSIDERATION OF DOCUMENTS CITED IN INTERNATIONAL SEARCH REPORT

Commissioner for Patents Alexandria, Virginia 22313

Sir:

In the matter of the above-identified application for patent, notice is hereby given that applicant(s) request that the Examiner consider the documents cited in the International Search Report according to MPEP §609 and so indicate by a statement in the first Office Action that the information has been considered. When the Form PCT/DO/EO/903 indicates both the search report and copies of the documents are present in the national stage file, there is no requirement for the applicant(s) to submit them (1156 O.G. 91 November 23, 1993).

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon Attorney of Record Registration No. 24,618 Surinder Sachar

Registration No. 34,423

Customer Number 22850

(703) 413-3000 Fax No. (703) 413-2220 (OSMMN 08/03)